Author + information
- Slobodan Dusan Obradovic,
- Boris Dzudovic,
- Bojana Subotic,
- Danijela Vranes and
- Nenad Ratkovic
Background: The stratification of bleeding risk for patients with pulmonary embolism (PE) and establishment of its role in the management of PE is urgently needed.
Methods: In a group of 206 consecutive PE patients, in a single center, three scores were assessed at baseline: HASS3B2E2D as newly composed score, HAS-BLED and VTE-BLEED. Patients were divided into two groups: the high-risk and the low-risk group, according to each score, and frequencies of major bleeding events were followed during the period of six-month. Values of the major bleeding prediction at six days and overall six-month bleeding were compared between three scores.
Results: According to HASS3B2E2D score, patients in the high-risk group had a bleeding incidence of 18.0% compared to 2.1% in the low-risk group for the first six days (OR=10.2; 95% CI 2.3-45.5, p<0.001) and 24.3% compared to 3.2% for overall six months period (OR=9.9; 95% CI 2.8-33.7, p<0.001). When VTE-BLEED score was used, major bleeding events in the high-risk vs. low-risk group were 15.3% vs. 6.5%, (OR=2.6; 95% CI 1.0-6.7,p=0.045) and 23.5% vs. 6.5% (OR=4.4; 95% CI 1.8-10.9, p=0.001), for the six-day and six-month period, respectively. HAS-BLED score showed major bleeding incidence in the first six days 18.5% vs. 7.1%, for the high-risk vs. low-risk group, respectively (OR=3.0; 95% CI 1.2-7.3, p=0.026), and 24.6% vs. 9.9% (OR=3.0; 95% CI 1.3-6.5, p=0.01) for overall six-month period. Among the three scores, HASS3B2E2D score had the strongest predictive power according the c-statistic: 0.71, 95% CI 0.61-0.80 and 0.71, 95% CI 0.63-0.80, for six-day and six-month period, respectively.
Conclusions: Our newly composed HASS3B2E2D score had the strongest power for the prediction of both early and late major bleeding events among PE patients.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Updates on Pulmonary Embolism Management in 2017
Abstract Category: 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease
Presentation Number: 1141-004
- 2017 American College of Cardiology Foundation